VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
QTTBQ32 Bio Inc.$12.70$162M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksQTTBPrice Target

QTTB logoQ32 Bio Inc. (QTTB) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated Jun 5, 2026

Current Price
$12.70
Market reference
Price Target
$13.50
+6.3% Upside
Target Range
$13.00 — $14.00
High conviction
Analyst Rating
Hold
8 analysts
Forward P/E—
Trailing P/E5.2x
Forward PEG—
Implied Growth-177.0%
Median Target$13.50
Analyst Spread7.4%

QTTB trades near analyst consensus with +6.3% potential upside. Limited near-term catalysts may be priced in at current levels.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$12.70
Consensus$13.50
High$14.00
Low$13.00
Model$18.95
Bear Case
$13
+2.4%
Consensus
$14
+6.3%
Bull Case
$14
+10.2%
Valuation Model TargetsConfidence: 26/100
Bear$13
Base$19
Bull$349

Analyst Ratings Distribution

Breakdown of 8 published analyst recommendations for QTTB

63% hold / mixed conviction
+19
BearishBullish
Weighted analyst sentiment score based on 8 ratings
ConsensusHold
Coverage8 Analysts
Net Score+19
Bull / Bear38% / 0%
Strong Buy00%
Buy338%
Hold563%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
338%
Hold
563%
Sell
00%
Strong Sell
00%
Recommendation Mix38% Buy · 63% Hold · 0% Sell
Buy (3)Hold (5)Sell (0)

QTTB Price Target Analysis

Updated June 12, 2026

As of June 12, 2026, Q32 Bio Inc. (QTTB) has a Wall Street consensus price target of $13.50, based on estimates from 8 covering analysts. With the stock currently trading at $12.70, this represents a potential upside of +6.3%. The company has a market capitalization of $162M.

Analyst price targets range from a low of $13.00 to a high of $14.00, representing a 7% spread in expectations. The median target of $13.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.

The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.

From a valuation perspective, QTTB trades at a trailing P/E of 5.2x. Analysts expect EPS to grow -177.0% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $18.95, with bear and bull scenarios of $13.26 and $349.02 respectively. Model confidence stands at 26/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+102.0%
Avg Forward P/E58.4x
Peers with Coverage10 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
AKRO logoAKROAkero Therapeutics, Inc.$4.5B$54.65$48.40-11.4%Buy—14
IMVT logoIMVTImmunovant, Inc.$6.8B$32.88$43.67+32.8%Buy—23
ARQT logoARQTArcutis Biotherapeutics, Inc.$3.1B$24.59$34.00+38.3%Buy123.5x12
CABA logoCABACabaletta Bio, Inc.$491M$3.01$16.33+442.5%Buy—12
TERN logoTERNTerns Pharmaceuticals, Inc.$4.8B$52.95$58.13+9.8%Buy—16
PRAX logoPRAXPraxis Precision Medicines, Inc.$7.2B$247.98$595.93+140.3%Buy—16
ALNY logoALNYAlnylam Pharmaceuticals, Inc.$38.6B$289.39$445.67+54.0%Buy38.6x52
REGN logoREGNRegeneron Pharmaceuticals, Inc.$63.5B$611.48$843.84+38.0%Buy13.2x48
SANA logoSANASana Biotechnology, Inc.$771M$2.77$8.67+213.0%Buy—11
BEAM logoBEAMBeam Therapeutics Inc.$3.0B$29.41$48.00+63.2%Buy—27

Upside Potential Comparison

CABA logoCABA
+442.5%
SANA logoSANA
+213.0%
PRAX logoPRAX
+140.3%
BEAM logoBEAM
+63.2%
ALNY logoALNY
+54.0%
ARQT logoARQT
+38.3%
REGN logoREGN
+38.0%
IMVT logoIMVT
+32.8%

What if you invested $1,000 in QTTB 10 years ago?

Total return calculator · dividends reinvested

Calculate Returns

How much would $100/month in QTTB be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is QTTB Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

QTTB vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

QTTB — Frequently Asked Questions

Quick answers to the most common questions about buying QTTB stock.

What is the QTTB stock price target for 2026?

The consensus price target for QTTB is $13.5, close to the current price of $12.7 (6.3% implied move). Based on 8 analyst estimates, the stock appears fairly valued near current levels.

Is QTTB a buy, sell, or hold?

QTTB has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $13.5 implies 6.3% upside from current levels.

Is QTTB stock overvalued or undervalued?

QTTB's current price is $12.7 with a consensus target of $13.5 (6.3% implied move). Analyst estimates suggest the stock is fairly valued at current levels.

How high can QTTB stock go?

The most bullish Wall Street analyst has a price target of $14 for QTTB, while the most conservative target is $13. The consensus of $13.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $349 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover QTTB stock?

QTTB is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the QTTB stock forecast?

The 12-month QTTB stock forecast based on 8 Wall Street analysts shows a consensus price target of $13.5, with estimates ranging from $13 (bear case) to $14 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $19, with bear/bull scenarios of $13/$349.

What is QTTB's fair value based on fundamentals?

Our quantitative valuation model calculates QTTB's fair value at $19 (base case), with a bear case of $13 and bull case of $349. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 26/100.

Should I buy QTTB stock?

QTTB appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $13.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do QTTB price targets vary so much?

QTTB analyst price targets range from $13 to $14, a 7% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13.5 consensus represents the middle ground. Our model's $13-$349 range provides an independent fundamental perspective.